Seminars in Hematology
Volume 40, Issue 1 , Pages 59-71, January 2003

Allogeneic stem cell transplantation for chronic myeloid leukemia☆☆☆

Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.

Abstract 

Allogeneic stem cell transplantation (SCT) plays a central role in chronic myeloid leukemia (CML) because it remains the only treatment with proven curative potential. For this reason, SCT has been more frequently performed in CML than in any other disease. The susceptibility of CML to the graft-versus-leukemia (GVL) effect and our ability to monitor minimal residual disease are particular features that place this disease at the forefront of GVL research. This review describes the mechanism of cure of CML by SCT, current results of transplantation, factors determining outcome, management of relapsed or persistent disease, and recent treatment advances. Semin Hematol 40:59-71. This is a US government work. There are no restrictions on its use.

 

☆ Address reprint requests to John Barrett, MD, Hematology Branch, NIH-NHLB1, Building 10 Room 7C103, 9000 Rockville Pike, Bethesda MD 20892-0003.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0037-1963(03)70043-2

Seminars in Hematology
Volume 40, Issue 1 , Pages 59-71, January 2003

Article Tools

* Image Usage & Resolution